InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,220.00
(
-0.20%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.39
(
0.00%
)
Bitcoin
64,234.77
(
0.23%
)
Post# of 252302
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 833
Posts 119891
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: mcbio post# 108120

Thursday, 11/04/2010 10:05:49 PM

Thursday, November 04, 2010 10:05:49 PM

Post# of 252302
Re: Copaxone litigation

I would assume you are fairly confident that MNTA will in fact succeed on this argument.

Actually, I don’t think MNTA is a favorite to win the case via any individual argument, but they have four ways to win, which makes MNTA a solid favorite to win the case via some argument.

My wild guesses are that MNTA has a 40% chance to prevail on the obviousness/double-patenting argument, a 30% chance to prevail on non-infringement, a 10% chance to prevail on indefiniteness, and a 5% chance to prevail on inequitable conduct. If you do the arithmetic, the above probabilities yield a 64% chance for MNTA to win the case by some method.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up